ImClone drug extends life in head, neck cancer patients
16th Nov 2005, 16:41 GMT
BOSTON (Reuters) - ImClone Systems Inc. said on Wednesday that a late-stage trial of its cancer drug Erbitux showed patients with head and neck cancer lived an average of 19.7 months longer than patients just treated with radiation.
ImClone drug extends life in head, neck cancer patients related news:
- ImClone drug extends life in head, neck cancer patients (Reuters) —
- ImClone drug extends life in head and neck cancer (Reuters) —
- Erbitux produces survival benefit in head and neck cancer — Pharmaceutical Business Review Online
- Scots are given new breast cancer drug a year before England — Scotsman.com News - Health
- Scots given new breast cancer drug a year before England — Scotsman.com News
- Imclone Study Shows Head Cancer Benefit and U.S. BioDefense, Inc. Explores Strategic Response to Bird Flu — Financial News USA (OTC: FNWU)
- Combination treatment for brain cancer not detrimental to patients' quality of life — Medical News Today RSS/XML Feed
- Australian prostate cancer drug shows promise — KeralaNext: Science
- Ovarian cancer patients' receptivity to therapy can be determined by genes — The Cancer Blog
- Cancer drug to benefit Scots first — the Mail online | Health news
Latest news from Reuters: Health:
- Camel milk ice cream to help trim Indian waists
- Diseased gums raise risk of pancreatic cancer
- FDA staff urges new caution on Roche flu drug
- Simple steps can speed heart attack care: study
- Children showing hardening of arteries: U.S. study
- Antibodies destroy HIV-infected cells
- New drug comb may lengthen ovarian cancer survival
- FDA OKs Genentech drug for early breast cancer
- Drug switch improves breast cancer survival: study